Press Releases Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
18.55 ^USD	+0.71%		+4.10%	+28.64%

09/04	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT
08/04	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	08/04	BU
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	08/04	BU
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	08/03	AQ
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	21/02	AQ
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	20/02	BU
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	20/02	AQ
Organon: Q4 Earnings Snapshot	15/02	AQ
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02	BU
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024	01/02	BU
Organon's XACIATO Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	11/01	AQ
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older	10/01	BU
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook	08/01	BU
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference	21/12	BU
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines	18/12	BU
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference	21/11	BU
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®	08/11	AQ
Organon: Q3 Earnings Snapshot	02/11	AQ
Organon Reports Results for the Third Quarter Ended September 30, 2023	02/11	BU
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed	01/11	BU
Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*	26/23/26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Organon & Co.

Equities

OGN

US68622V1061

Press Releases

Filters